There’s a right way to regulate drugs. Kratom is no exception.

Andrew Kolodny’s July 17 op-ed, “My patients are becoming addicted to this ‘supplement,’” was correct that scheduling 7-hydroxymitragynine, or 7-OH, while leaving other kratom products unregulated is incoherent policymaking. But there’s a critical element lacking in the current scheduling effort. W...

Redirecting to full article...